Insider Trading May 4, 2026 04:26 PM

First Guaranty Bancshares Director Executes Significant Stock Purchase Amid Recent Rally

Bruce McAnally acquires nearly $1 million in common stock through an irrevocable asset trust as the company approaches upcoming earnings report.

By Caleb Monroe FGBI
First Guaranty Bancshares Director Executes Significant Stock Purchase Amid Recent Rally
FGBI

A significant insider transaction has been recorded at First Guaranty Bancshares, Inc. (NASDAQ: FGBI). Bruce McAnally, a member of the company's board of directors, completed a substantial purchase of common stock on April 30, 2026. The acquisition involved 109,051 shares, purchased at an individual share price of $9.17. This transaction represents a total investment of approximately $999,997.The purchase was conducted indirectly through the BMAC Irrevocable Asset Trust, for which Mr. McAnally acts as trustee. Following this latest movement, the trust's holdings in the company have risen to 441,587 shares. While Mr. McAnally holds a pecuniary interest in these securities, he has disclaimed beneficial ownership except to that specific extent. This transaction occurs against a backdrop of recent market activity for FGBI, which has seen its stock price increase by 60% over the last six months and is currently trading at $9.00, with a total market capitalization of $144 million.

Key Points

  • Director Bruce McAnally purchased $999,997 worth of FGBI stock through a trust.
  • The company is amending loan agreements with an affiliate-controlled entity to allow for interest payments in stock or cash.
  • FGBI has seen a 60% stock surge over six months but faces concerns regarding being overvalued.

Insider Activity and Ownership Structure

The recent acquisition by Director Bruce McAnally highlights an extensive network of holdings within First Guaranty Bancshares. Beyond the BMAC Irrevocable Asset Trust, Mr. McAnally maintains several other interests in the company's common stock. These include 3,253 shares held directly, which are under joint ownership with his spouse. He also manages various indirect interests through different vehicles: 1,572 shares are held via an IRA, 220 shares through a Roth IRA, and another 2,583 shares are held in his spouse’s IRA. Regarding the latter, Mr. McAnally has disclaimed beneficial ownership of those specific shares except to the extent of his pecuniary interest.

The scope of indirect holdings extends further into other trusts and entities. The TMAC Irrevocable Asset Trust, where Mr. McAnally serves as trustee, holds 10,678 shares. Additionally, an affiliate known as Medicine Shoppes, Inc. holds 633 shares. Furthering this complexity, the Tina McAnally 2007 Trust holds 11,403 shares, with an additional 385 shares held by Keestra Financial (McKinney Wealth Management) for that same trust. In these instances, Mr. McAnally has disclaimed beneficial ownership except to the extent of his pecuniary interest.

Corporate Governance and Strategic Amendments

First Guaranty Bancshares has also undergone recent changes in its leadership and contractual arrangements. According to filings with the Securities and Exchange Commission, Betsy K. Hood has been elected to the company's board of directors. While she has not been assigned to any specific board committees at this time, her election is a notable development for the board's composition.

Furthermore, the company has implemented amendments to two loan agreements involving Smith & Tate Investment, L.L.C. This firm is controlled by Edgar Ray Smith, III, who is both a principal shareholder and a director at First Guaranty Bancshares. The amended terms include a waiver regarding principal payments for the period spanning March 31, 2026, through March 31, 2028. During this two-year window, the company is also permitted to fulfill interest payments using either cash or shares of its common stock.

Market Context and Valuation

The timing of this insider purchase is noteworthy as First Guaranty Bancshares prepares to report earnings on May 4, 2026. While the stock has experienced a significant 60% surge over the preceding six months, valuation metrics provide a different perspective. Analysis suggests that FGBI appears to be overvalued relative to its Fair Value, placing it on a list of stocks characterized as most overvalued.


Key Market Insights

  • Insider Confidence in Banking Sector: The nearly $1 million purchase by a director suggests internal activity during a period of significant price appreciation for the stock.
  • Strategic Financial Adjustments: The amendments to loan agreements with Smith & Tate Investment, L.L.C., involving principal payment waivers and flexible interest settlements, indicate active management of the company's liquidity and debt obligations.

Potential Risks and Uncertainties

  • Valuation Concerns: Current analysis indicates that FGBI may be trading at levels significantly above its estimated Fair Value, which could pose risks to investors following the recent 60% rally.
  • Earnings Volatility: With earnings scheduled for May 4, 2026, the company faces immediate uncertainty regarding how financial performance will impact the stock price in the short term.

Risks

  • Stock valuation risk as FGBI is currently identified as overvalued relative to its Fair Value.
  • Upcoming earnings report on May 4, 2026, introduces short-term volatility risks.

More from Insider Trading

Cheesecake Factory CEO Executes $6.3 Million Stock Sale Amid Recent Earnings Beat May 4, 2026 Emergent BioSolutions Director Keith Katkin Executes Stock Sales and Receives New Equity Grants May 4, 2026 Emergent BioSolutions Director Executes Stock Sales Under Pre-Arranged Plan May 4, 2026 Emergent BioSolutions Director Executes Stock Sale Under Rule 10b5-1 Plan May 4, 2026 Westwood Holdings Group Emerita Director Executes Scheduled Stock Sales May 4, 2026